| Title |
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing: 2014 Update
|
|---|---|
| Published in |
Clinical Pharmacology & Therapeutics, February 2014
|
| DOI | 10.1038/clpt.2014.38 |
| Pubmed ID | |
| Authors |
M A Martin, J M Hoffman, R R Freimuth, T E Klein, B J Dong, M Pirmohamed, J K Hicks, M R Wilkinson, D W Haas, D L Kroetz |
| Abstract |
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org). |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 212 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Hungary | 1 | <1% |
| Malaysia | 1 | <1% |
| France | 1 | <1% |
| India | 1 | <1% |
| Mexico | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 206 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 39 | 18% |
| Student > Master | 27 | 13% |
| Student > Ph. D. Student | 24 | 11% |
| Other | 22 | 10% |
| Student > Bachelor | 18 | 8% |
| Other | 47 | 22% |
| Unknown | 35 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 55 | 26% |
| Biochemistry, Genetics and Molecular Biology | 35 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 29 | 14% |
| Agricultural and Biological Sciences | 23 | 11% |
| Engineering | 5 | 2% |
| Other | 28 | 13% |
| Unknown | 37 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2021.
All research outputs
#1,404,723
of 23,818,521 outputs
Outputs from Clinical Pharmacology & Therapeutics
#191
of 4,275 outputs
Outputs of similar age
#14,704
of 225,978 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#5
of 35 outputs
Altmetric has tracked 23,818,521 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,275 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 225,978 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.